Beckman Research Institute is located in Duarte, CA. The organization was established in 2005. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. As of 09/2023, Beckman Research Institute employed 1,248 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Beckman Research Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 09/2022, Beckman Research Institute generated $288.3m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 7 years, the organization has seen revenues fall by an average of (3.5%) each year. All expenses for the organization totaled $367.6m during the year ending 09/2022. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
TO DISCOVER AND TRANSLATE INNOVATIVE LABORATORY FINDINGS INTO NEW CLINICAL TREATMENTS BY USING PRACTICAL APPLICATIONS OF CHEMISTRY, PHYSICS AND BIOLOGY.
Describe the Organization's Program Activity:
Part 3 - Line 4a
BIOMEDICAL RESEARCH AND DISEASE INVESTIGATIONS, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. BECKMAN RESEARCH INSTITUTE HAS PIONEERED SCIENTIFIC BREAKTHROUGHS RESULTING IN TREATMENTS THAT HAVE IMPROVED THE LIVES OF PATIENTS WORLDWIDE. NUMEROUS LIFE-SAVING DRUGS USE PATENTED TECHNOLOGY DEVELOPED AT BECKMAN RESEARCH INSTITUTE. THESE DRUGS INCLUDE SYNTHETIC HUMAN INSULIN (HUMULIN) FOR DIABETES, THE WIDELY USED CANCER DRUGS HERCEPTIN, RITUXAN AND AVASTIN, AND HUMIRA FOR ARTHRITIS. RESEARCHERS AT BECKMAN RESEARCH INSTITUTE UNDERTAKE FUNDAMENTAL INVESTIGATIONS IN DIABETES PROGRESSION AND TREATMENT, IMMUNOLOGY AND IMAGING, INTERFERING RNAS AND HIV TREATMENT, TOTAL SYNTHESIS OF COMPLEX AND THERAPEUTIC NATURAL PRODUCTS, MECHANISMS OF DRUG ACTION, NEUROGENESIS, STEM CELL THERAPY, DNA REPAIR AND RADIATION, AND THE IMMUNOBIOLOGY OF VIRAL INFECTION. THEY HAVE ACHIEVED MAJOR ADVANCES IN RECOMBINANT DNA TECHNOLOGY, MONOCLONAL ANTIBODIES, GENE THERAPY, EPIGENETICS, SI-RNA TECHNOLOGY AND CANCER IMMUNOTHERAPEUTICS. A DEPARTMENT IN BECKMAN RESEARCH INSTITUTE IS DEDICATED TO UNDERSTANDING AND DEVELOPING TREATMENTS BASED ON CANCER'S INTERACTION WITH THE IMMUNE SYSTEM. OTHER RESEARCH HAS IDENTIFIED PROTEINS THAT MAY PLAY CRITICAL ROLES IN IMMUNE RESPONSE AND MAY LEAD TO NEW TREATMENT STRATEGIES. ANOTHER MAJOR EMPHASIS FOR THE BECKMAN RESEARCH INSTITUTE SCIENTISTS IS PERSONALIZED RESEARCH AND MEDICINE -- ANALYZING A PATIENT'S UNIQUE GENETIC PROFILE TO DEVELOP TAILORED THERAPIES FOR THEIR SPECIFIC DISEASE. ALL OF THIS RESEARCH IS UNIQUELY SUPPORTED BY ONSITE MANUFACTURING FACILITIES THAT CAN TEST AND PRODUCE QUANTITIES OF CELL-BASED, GENE-BASED AND MOLECULAR THERAPIES. THESE FACILITIES FURTHER SERVE AS RESOURCES FOR MEDICAL AND SCIENTIFIC RESEARCH CENTERS NATIONWIDE. BECKMAN RESEARCH INSTITUTE SCIENTISTS SERVE AS FACULTY MEMBERS IN CITY OF HOPE'S IRELL & MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. THE GRADUATE SCHOOL'S MISSION IS TO TRAIN STUDENTS TO BE OUTSTANDING RESEARCH SCIENTISTS IN CHEMICAL, MOLECULAR AND CELLULAR BIOLOGY. THE SCHOOL IS ACCREDITED BY THE WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES. GRADUATES OF THE PROGRAM, AWARDED A DOCTORATE OF PHILOSOPHY IN BIOLOGICAL SCIENCES, ARE EQUIPPED TO ADDRESS FUNDAMENTAL QUESTIONS IN LIFE SCIENCES AND BIOMEDICINE FOR CAREERS IN ACADEMIA, INDUSTRY AND GOVERNMENT.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Name Not Listed Director & Chair Of The Board | OfficerTrustee | 2 | $0 |
Name Not Listed Director | Trustee | 2 | $0 |
Name Not Listed Director; Professor | Trustee | 60 | $435,517 |
Name Not Listed Director | Trustee | 2 | $0 |
Name Not Listed Director | Trustee | 2 | $0 |
Name Not Listed Director | Trustee | 2 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Mintz Levin Cohn Ferris Glovsky And Popeo Pc Legal Services | 9/29/23 | $3,420,972 |
Fish & Richardson Pc Legal Services | 9/29/23 | $1,372,605 |
Bioreliance Corporation Testing & Manufacturing Services | 9/29/23 | $1,381,942 |
Lcs Constructors Inc Construction Services | 9/29/23 | $1,128,731 |
Pacific Rim Mechanical Construction Services | 9/29/23 | $1,140,655 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $48,853,255 |
Government grants | $98,626,185 |
All other contributions, gifts, grants, and similar amounts not included above | $6,673,438 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $154,152,878 |
Total Program Service Revenue | $25,203,801 |
Investment income | $14,429,552 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $12,755,042 |
Net Rental Income | $86,500 |
Net Gain/Loss on Asset Sales | $79,091,943 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $288,276,013 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $7,033,214 |
Compensation of current officers, directors, key employees. | $4,747,948 |
Compensation to disqualified persons | $352,259 |
Other salaries and wages | $152,712,668 |
Pension plan accruals and contributions | $9,190,968 |
Other employee benefits | $16,510,042 |
Payroll taxes | $10,054,743 |
Fees for services: Management | $0 |
Fees for services: Legal | $6,570,522 |
Fees for services: Accounting | $44,681 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $2,657,517 |
Fees for services: Other | $47,754,950 |
Advertising and promotion | $2,790,755 |
Office expenses | $5,835,364 |
Information technology | $9,829,543 |
Royalties | $6,409,110 |
Occupancy | $13,172,671 |
Travel | $1,356,022 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $564,976 |
Interest | $4,702,704 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $27,539,979 |
Insurance | $1,158,745 |
All other expenses | $3,976,190 |
Total functional expenses | $367,599,613 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $7,545,012 |
Savings and temporary cash investments | $17,336,792 |
Pledges and grants receivable | $35,176,879 |
Accounts receivable, net | $13,521,672 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $5,753,644 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $306,843 |
Net Land, buildings, and equipment | $300,180,002 |
Investments—publicly traded securities | $282,925,843 |
Investments—other securities | $897,988,765 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $194,535,097 |
Total assets | $1,755,270,549 |
Accounts payable and accrued expenses | $42,372,436 |
Grants payable | $0 |
Deferred revenue | $9,407,922 |
Tax-exempt bond liabilities | $50,104,751 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $50,000,000 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $475,008,805 |
Total liabilities | $626,893,914 |
Net assets without donor restrictions | $1,100,918,157 |
Net assets with donor restrictions | $27,458,478 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $1,755,270,549 |